Danisco US Inc.

Ribotargets Limited

Genencor International, Inc.

Medical Research Council

Danisco US Inc., Genencor Division

Danisco A/s, Genencor Division

Ribotargets Holdings Plc

Shaun Heaphy

Brian E Jones

William Duncan Grant

Susan Grant

Jonathan Karn

Michael John Gait

Helen Rees

Colin Dingwall

Helen C Rees

Brian Edward Jones

The present invention provides a novel nucleic acid sequence, designated LIP1, encoding a lipolytic enzyme and the corresponding encoded amino acid sequences. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding at least one novel lipolytic enzyme, recombinant lipolytic enzyme proteins and methods for producing the same.

Lipolytic enzyme LIP1

The present invention provides a novel nucleic acid sequence, designated LIP2, encoding a lipolytic enzyme and the corresponding encoded amino acid sequences. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding at least one novel lipolytic enzyme, recombinant lipolytic enzyme proteins and methods for producing the same.

Lipolytic enzyme LIP2

The present invention provides a novel nucleic acid sequence, designated ELIP, encoding a lipolytic enzyme and the corresponding encoded amino acid sequences. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding at least one novel lipolytic enzyme, recombinant lipolytic enzyme proteins and methods for producing the same.

Lipolytic enzyme ELIP

The present invention provides a novel cellulase nucleic acid sequence, designated 029cel, and the corresponding 029cel amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding 029cel, recombinant 029cel proteins and methods for producing the same.

Bacillus 029cel cellulase

The present invention provides a novel cellulase nucleic acid sequence, designated BagCel, and the corresponding BagCel amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding BagCel, recombinant BagCel proteins and methods for producing the same.

[object Object]

The present invention provides a novel cellulase nucleic acid sequence, designated mHKcel, and the corresponding mHKcel amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding mHKcel, recombinant mHKcel proteins and methods for producing the same.

The present invention provides a novel cellulase nucleic acid sequence, designated 029cel, and the corresponding 029cel amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding 029cel, recombinant 029cel proteins and methods for producing the same. 

Lipolytic enzyme elip

A synthetic molecule comprises at least one oligonucleotide comprising an RNA binding sequence or sequences corresponding to the site bound by the HIV protein rev and capable of binding ot rev within cells. The binding sequence or sequences, by binding with rev within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients infected with HIV. The invention also provides an assay for identifying that inhibit rev binding.

Viral growth inhibition

A synthetic molecule comprises at least one oligonucleotide, comprising and RNA binding sequence or sequences corresponding to the site bound by the HIV protein tat and capable of binding to tat within cells. The binding sequence or sequences, by binding tat within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients affected with HIV. The invention also provides an assay for identifying compounds that inhibit tat binding.

Viral (HIV) growth inhibition

A synthetic molecule comprising an RNA binding sequence or sequences corresponding to the site bound by the HIV protein tat and capable of binding to tat within cells. The binding sequence or sequences, by binding tat within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients affected with HIV. The invention also provides an assay for identifying compounds that inhibit tat binding.

RNA oligonucleotides that bind HIV tat protein

A synthetic molecule comprises at least one oligonucleotide comprising an RNA binding sequence or sequences corresponding to the site bound by the HIV protein rev and capable of binding to rev within cells. The binding sequence or sequences, by binding rev within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients infected with HIV. The invention also provides an assay for identifying compounds that inhibit rev binding.

Growing community of inventors

Leicester, United Kingdom

Shaun Heaphy